April 12 (Reuters) - Genetic Technologies Ltd GTG.AX :* GENETIC TECHNOLOGIES APPOINTS MIKE TONROE AS CFO* GENETIC TECHNOLOGIES LTD - ANNOUNCES APPOINTMENT OF MICHAEL TONROE TO...
March 4 (Reuters) - Genetic Technologies Ltd GTG.AX :* GENETIC TECHNOLOGIES SIGNS MULTI-YEAR US DISTRIBUTION AGREEMENT FOR COVID RISK TEST* GENETIC TECHNOLOGIES LTD - CO SIGNS...
March 3 (Reuters) - Genetic Technologies Ltd GTG.AX :* CO-EXCLUSIVE PRODUCTION AND DISTRIBUTION RIGHTS AND LICENSE AGREEMENT WITH US BASED INFINITY BIOLOGIX LLC* DEAL FOR...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Technical Indicators | Neutral | Neutral | Buy | Sell | Buy |
| Summary | Sell | Sell | Neutral | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.55 | 0.00 | 0.00 | -0.020 | -3.51% | 27.42K | Sydney | |||
| 0.11 | 0.00 | 0.00 | +0.010 | +10.00% | 1.12M | Sydney | |||
| 15.20 | 15.50 | 15.18 | -0.37 | -2.38% | 2.13M | Sydney | |||
| 14.76 | 14.82 | 14.60 | +0.130 | +0.89% | 8.47M | Sydney | |||
| 0.75 | 0.00 | 0.00 | -0.010 | -1.32% | 189.75K | Sydney | |||
| 0.065 | 0.00 | 0.00 | +0.001 | +1.56% | 269.61K | Sydney | |||
| 15.33 | 15.60 | 15.17 | +0.10 | +0.66% | 1.52M | Sydney | |||
| 1.125 | 1.16 | 1.03 | +0.105 | +10.29% | 6.13M | Sydney | |||
| 10.63 | 10.78 | 10.51 | +0.08 | +0.76% | 396.06K | Sydney | |||
| 43.35 | 43.78 | 43.15 | -0.350 | -0.80% | 4.59M | Sydney | |||
| 5.54 | 5.55 | 5.54 | 0.000 | 0.00% | 0.00 | Sydney | |||
| 75.96 | 76.57 | 75.43 | +0.03 | +0.04% | 534.84K | Sydney | |||
| 8.09 | 8.19 | 7.81 | -0.020 | -0.25% | 599.13K | Sydney | |||
| 124.23 | 125.30 | 122.60 | -1.480 | -1.18% | 1.98M | Sydney | |||
| 4.15 | 4.24 | 4.13 | -0.030 | -0.72% | 7.40M | Sydney |
Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.